Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study
Authors
Pengcheng He (ORCID: https://orcid.org/0000-0002-0764-2458)
Xue Gai (ORCID: https://orcid.org/0000-0003-4774-0607)
Xinchao Luo
Thomas Renaud (ORCID: https://orcid.org/0000-0002-4895-6090)
Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study
Pengcheng He, Xue Gai, Xinchao Luo, Thomas Renaud et al.
Citations
1 citations
Journal
Haematologica
Topics
Multiple Myeloma Research and Treatments
Field-Weighted Citation Impact (FWCI)
1.77
article
Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study
Pengcheng He, Xue Gai, Xinchao Luo, Thomas Renaud, Tara Masterson, Binbin Sun, Chengcheng Fu, Zhongjun Xia, Zhen Cai, Deeksha Vishwamitra, Bonnie Lau, Christoph Heuck, Hong Zhang, Rui Liu, Li Liang, Jie Jin, Gang An, Hongmei Xu, Indrajeet Singh, Michela Campagna, Hongmei Jing, Longen Zhou, Dian Zhu, Lugui Qiu
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Haematologica
Institutions
Johnson & Johnson (United States) (US), Sun Yat-sen University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Soochow University (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), Johnson & Johnson (Israel) (IL), Johnson & Johnson (United Kingdom) (GB), Peking University Third Hospital (CN), Sun Yat-sen University Cancer Center (CN), Institute of Hematology & Blood Diseases Hospital (CN), First Affiliated Hospital of Soochow University (CN), First Affiliated Hospital Zhejiang University (CN)